BriaCell Therapeutics Corp Cash Flow Conversion Efficiency
BriaCell Therapeutics Corp cash flow conversion efficiency. Based on the latest financial reports, BriaCell Therapeutics Corp (BCTXW) has a cash flow conversion efficiency ratio of -0.270x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.09 Million) by net assets ($29.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BriaCell Therapeutics Corp (2006–2025)
Cash flow conversion efficiency of BriaCell Therapeutics Corp from 2006 to 2025. This chart illustrates how BriaCell Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BriaCell Therapeutics Corp stock quote for real-time trading data and today's change.
BriaCell Therapeutics Corp Cash Flow Conversion Ratio Explained
BriaCell Therapeutics Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BriaCell Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BriaCell Therapeutics Corp ranked by their cash flow conversion efficiency. Also see how much is BriaCell Therapeutics Corp worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Waldencast Acquisition Corp
NASDAQ:WALDW
|
-0.003x |
|
Aquis Exchange PLC
LSE:AQX
|
0.057x |
|
Lexaria Bioscience Corp
NASDAQ:LEXXW
|
-0.218x |
|
Jasmine International Public Company Limited
F:JASN
|
0.020x |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
-0.017x |
|
immatics biotechnologies GmbH
NASDAQ:IMTXW
|
-0.064x |
|
Neovacs S.A.
PA:ALNEV
|
-0.144x |
|
African Agriculture Holdings Inc.
NASDAQ:AAGR
|
0.078x |
Annual Cash Flow Conversion Efficiency for BriaCell Therapeutics Corp (2006–2025)
The table below shows the annual cash flow conversion efficiency of BriaCell Therapeutics Corp from 2006 to 2025. Review BriaCell Therapeutics Corp (BCTXW) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $17.33 Million | $-28.17 Million | -1.625x | -118.09% |
| 2024-07-31 | $-2.68 Million | $-24.13 Million | 8.986x | +42.94% |
| 2023-07-31 | $-3.78 Million | $-23.74 Million | 6.286x | +620.10% |
| 2022-07-31 | $10.33 Million | $-12.48 Million | -1.209x | -793.31% |
| 2021-07-31 | $57.26 Million | $-7.75 Million | -0.135x | -138.45% |
| 2020-07-31 | $-3.29 Million | $-1.16 Million | 0.352x | -94.16% |
| 2019-07-31 | $-643.49K | $-3.87 Million | 6.021x | +249.52% |
| 2018-07-31 | $945.02K | $-3.81 Million | -4.027x | -96.79% |
| 2017-07-31 | $750.23K | $-1.54 Million | -2.046x | -34.33% |
| 2016-07-31 | $787.11K | $-1.20 Million | -1.523x | -88.80% |
| 2015-07-31 | $1.16 Million | $-935.26K | -0.807x | -66.56% |
| 2014-07-31 | $751.30K | $-363.97K | -0.484x | -1127.01% |
| 2013-07-31 | $9.33 Million | $-368.52K | -0.039x | -3.85% |
| 2012-07-31 | $10.03 Million | $-381.49K | -0.038x | +35.14% |
| 2011-07-31 | $11.79 Million | $-690.76K | -0.059x | +72.66% |
| 2010-07-31 | $1.44 Million | $-309.37K | -0.214x | -48.60% |
| 2009-07-31 | $974.50K | $-140.59K | -0.144x | +39.73% |
| 2008-07-31 | $365.17K | $-87.41K | -0.239x | -21.84% |
| 2007-07-31 | $446.71K | $-87.76K | -0.196x | -1492.28% |
| 2006-07-31 | $79.82K | $1.13K | 0.014x | -- |
About BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more